CTNM FY 2024 Earnings — Contineum Therapeutics, Inc. Class A Common Stock Revenue & Financial Results | Market Cap Arena

CTNMContineum Therapeutics, Inc. Class A Common Stock

$504M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$258,000

Operating Income

-$51M

Net Income

-$42M

EPS (Diluted)

$-2.18

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$33M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$213M

Total Liabilities

$15M

Stockholders' Equity

$198M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$50M	-100.0%
Gross Profit	-$258,000	$50M	-100.5%
Operating Income	-$51M	-$16M	-216.6%
Net Income	-$42M	$23M	-286.0%